<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144555">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01833585</url>
  </required_header>
  <id_info>
    <org_study_id>SIRIRAJR015533013</org_study_id>
    <nct_id>NCT01833585</nct_id>
  </id_info>
  <brief_title>Treatment of Chronic Critical Limb Ischemia With G-CSF-mobilized Autologous Peripheral Blood Mononuclear Cells</brief_title>
  <official_title>Pilot Study of Treatment of Chronic Critical Limb Ischemia With G-CSF-mobilized Autologous Peripheral Blood Mononuclear Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <authority>Thailand: Ethical Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of G-CSF-mobilized
      autologous peripheral blood mononuclear cell injection to ischemic limbs of patients with
      critical limb ischemia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of patients without major amputation after mononuclear cell injection</measure>
    <time_frame>3 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <condition>Atherosclerosis</condition>
  <condition>Ischemic Ulcer</condition>
  <condition>Gangrene</condition>
  <arm_group>
    <arm_group_label>peripheral blood mononuclear cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>peripheral blood mononuclear cells will be injected to calf muscle of critical limb ischemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peripheral blood mononuclear cell</intervention_name>
    <description>Peripheral blood mononuclear cell solution 59 cc will be injected to the gastrocnemius muscle of ischemic limb of patients with critical limb ischemia</description>
    <arm_group_label>peripheral blood mononuclear cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with critical limb ischemia confirmed by toe pressure, ABI, TCOM

          -  Levels of arterial occlusion are femoropopliteal or tibioperoneal occlusion

          -  Poor distal artery runoff

          -  Age 18-70 year

        Exclusion Criteria:

          -  Planned for major amputation within 4 weeks

          -  Receive blood component within 4 weeks

          -  Acute myocardial infarction

          -  severe valvular heart disease

          -  renal failure

          -  liver failure

          -  Cancer

          -  Hypercoagulable state

          -  Severe infection

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nuttawut Sermsathanasawadi, MD.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nuttawut Sermsathanasawadi, MD.,Ph.D</last_name>
    <email>nuttawut@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vascular Surgery, Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuttawut Sermsathanasawadi, MD., Ph.D</last_name>
      <email>nutttawut@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Nuttawut Sermsathanasawadi, MD., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 14, 2013</lastchanged_date>
  <firstreceived_date>April 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>critical limb ischemia</keyword>
  <keyword>atherosclerosis</keyword>
  <keyword>ischemic ulcer</keyword>
  <keyword>rest pain</keyword>
  <keyword>gangrene</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Gangrene</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
